![]() |
|
|
Vol. 27, Issue 10, 1143-1149, October 1999
Boehringer Ingelheim Pharma KG, Biberach, Germany
Telmisartan 1-O-acylglucuronide, the principal
metabolite of telmisartan in humans, was characterized in terms of
chemical stability and the structure of its isomerization products
was elucidated. In addition, pharmacokinetics of telmisartan
1-O-acylglucuronide were assessed in rats after i.v.
dosing. Similar to other acylglucuronides, telmisartan
1-O-acylglucuronide and diclofenac
1-O-acylglucuronide, which was used for comparison,
showed the formation of different isomeric acylglucuronides on
incubation in aqueous buffer. The isomeric acylglucuronides of
telmisartan consisted of the 2-O-, 3-O-,
and 4-O-acylglucuronides (
,
-anomers). First order
degradation half-lives of 26 and 0.5 h were observed on incubation
in buffer of pH 7.4 for the 1-O-acylglucuronides of
telmisartan and diclofenac, respectively. This indicated that the
1-O-acylglucuronide of telmisartan was among the most
stable acylglucuronides reported to date. The high stability of
telmisartan 1-O-acylglucuronide was confirmed by in
vitro experiments that indicated only very low covalent binding of
telmisartan acylglucuronide to human serum albumin but a considerable
amount of covalently bound radioactivity with the acylglucuronide of
diclofenac. After i.v. dosing to rats, telmisartan
1-O-acylglucuronide was rapidly cleared from plasma with
a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the
parent compound. Because telmisartan 1-O-acylglucuronide exhibited a comparably high chemical stability together with a high
clearance that resulted in low systemic exposure, the amount of
covalent binding to proteins should be negligible compared with other
frequently used drugs, such as furosemide, ibuprofen, or salicylic acid.
This article has been cited by other articles:
![]() |
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS Drug Metab. Dispos., January 1, 2006; 34(1): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Grillo, C. G. Knutson, P. E. Sanders, D. J. Waldon, F. Hua, and J. A. Ware STUDIES ON THE CHEMICAL REACTIVITY OF DICLOFENAC ACYL GLUCURONIDE WITH GLUTATHIONE: IDENTIFICATION OF DICLOFENAC-S-ACYL-GLUTATHIONE IN RAT BILE Drug Metab. Dispos., November 1, 2003; 31(11): 1327 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Perkins, J. W. Cramer, N. A. Farid, M. G. Gadberry, D. A. Jackson, E. L. Mattiuz, D. D. O'Bannon, H. J. Weiss, W. J. Wheeler, P. G. Wood, et al. PRECLINICAL CHARACTERIZATION OF 2-[3-[3-[(5-ETHYL-4'-FLUORO-2-HYDROXY[1,1'-BIPHENYL]-4-YL)OXY]PROPOXY]-2-PROPYLPHENOXY]BENZOIC ACID METABOLISM: IN VITRO SPECIES COMPARISON AND IN VIVO DISPOSITION IN RATS Drug Metab. Dispos., November 1, 2003; 31(11): 1382 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bolze, N. Bromet, C. Gay-Feutry, F. Massiere, R. Boulieu, and T. Hulot Development of an in Vitro Screening Model for the Biosynthesis of Acyl Glucuronide Metabolites and the Assessment of Their Reactivity toward Human Serum Albumin Drug Metab. Dispos., April 1, 2002; 30(4): 404 - 413. [Abstract] [Full Text] [PDF] |
||||